Hypertension in kidney disease
Renal parenchymal and renovascular hypertension, BP targets and drug choice across CKD, dialysis and transplant, and the renal emergencies where the right antihypertensive matters (scleroderma renal crisis).
Tier 1Condition
Written with AI assistance and fact-checked against the sources below. For exam study, not clinical decisions. How notes are made
At a glance
- Kidney disease is the commonest secondary cause of hypertension, and in Australia and NZ hypertension and renovascular disease are the third commonest cause of kidney failure, after diabetes and glomerulonephritis (ANZDATA; hypertension ranks second in US data). Each worsens the other.
- Renal parenchymal hypertension comes from sodium retention, RAAS activation and sympathetic overactivity. It affects most people with CKD G4 and nearly everyone on dialysis.
- Renovascular hypertension is atherosclerotic in about 90% (older, vascular disease) and fibromuscular dysplasia in most of the rest (mostly women, from young adulthood to middle age).
Loading the rest of the note…
Finished reading?
Sources
- Guideline for the diagnosis and management of hypertension in adults 2016AU/NZNational Heart Foundation of Australia, 2016 (replacement guideline announced as coming soon, not published as of November 2026)
- Chronic Kidney Disease (CKD) Management in Primary Care, 5th editionAU/NZKidney Health Australia, 2024
- KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney International 2021;99(3S):S1-S87Kidney Disease Improving Global Outcomes, 2021 (still current, checked November 2026)
- McEvoy JW et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J 2024;45:3912-4018European Society of Cardiology, 2024
- Mancia G et al. 2023 ESH Guidelines for the management of arterial hypertension. J Hypertens 2023;41:1874-2071European Society of Hypertension, 2023
- Agarwal R et al. Chlorthalidone for hypertension in advanced chronic kidney disease (CLICK). N Engl J Med 2021;385:2507-19New England Journal of Medicine, 2021
- Cooper CJ et al. Stenting and medical therapy for atherosclerotic renal-artery stenosis (CORAL). N Engl J Med 2014;370:13-22New England Journal of Medicine, 2014
- ASTRAL Investigators. Revascularization versus medical therapy for renal-artery stenosis. N Engl J Med 2009;361:1953-62New England Journal of Medicine, 2009
- Gornik HL et al. First international consensus on the diagnosis and management of fibromuscular dysplasia. Vasc Med 2019;24:164-89Vascular Medicine, 2019
- Schrier RW et al. Blood pressure in early autosomal dominant polycystic kidney disease (HALT-PKD). N Engl J Med 2014;371:2255-66New England Journal of Medicine, 2014
- Last updated
- 14 November 2026
What changed
- 14 November 2026 Turnstile bot check on sign-in and signed-out feedback